Richter Gedeon Vegyeszeti Gyar Rt

Emil Bittner

Karola Jovanovics

Kalman Szasz

Laszlo Nemeth

Bela Kellner

Zsuzsa Relle

Eszter Dezseri

Eszter Deszeri

N-formylleurosine or a pharmaceutically effective salt is used in human therapy for treatment of lymphoma, leukemia or Hodgkins Disease.

Method of treatment using new leurosine derivatives

Multiple myeloma in human patients is treated by administering N-formylleurosine or its sulfate salt.

New leurosine derivatives of the general formula (1), ##STR1## wherein R stands for hydrogen or formyl, or pharmaceutically acceptable acid addition salts thereof were prepared by oxidizing leurosine or an acid addition salt thereof, optionally formylating the thus-obtained product and then separating, and, if desired, converting any of the free bases into its acid addition salt.

N-Formyl leurosine derivatives in a dosage form effective for treating

Leurosine derivatives of the formula (I), ##STR1## wherein R is hydrogen or formyl, or pharmaceutically acceptable acid addition salts thereof were prepared by oxidizing leurosine or an acid addition salt thereof, optionally formylating the thus-obtained product and then separating, and, if desired, converting any of the free bases into its acid addition salt. The new compounds of the invention possess strong cytostatic activity, and can be used in the human therapy with great advantage.

Growing community of inventors

Budapest, Hungary

Emil Bittner